These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 22037027)

  • 21. The right to a trial: Should dying patients have access to experimental drugs?
    Groopman J
    New Yorker; 2006 Dec; ():40-7. PubMed ID: 17176539
    [No Abstract]   [Full Text] [Related]  

  • 22. Learning from the 2012-2013 class of breakthrough therapies.
    Mullard A
    Nat Rev Drug Discov; 2013 Dec; 12(12):891-3. PubMed ID: 24287765
    [No Abstract]   [Full Text] [Related]  

  • 23. FDA starts moving on critical path, but initiative running out of steam.
    Finkelstein JB
    J Natl Cancer Inst; 2007 Mar; 99(6):426-7. PubMed ID: 17374831
    [No Abstract]   [Full Text] [Related]  

  • 24. A voyage of discovery.
    Gebel E
    Diabetes Forecast; 2013 Jun; 66(6):50-3. PubMed ID: 23802293
    [No Abstract]   [Full Text] [Related]  

  • 25. A need for speed: Signals in drug development.
    Nat Med; 2012 Dec; 18(12):1730-1. PubMed ID: 23223053
    [No Abstract]   [Full Text] [Related]  

  • 26. Can single-patient investigational new drug studies hurry slow trains to the fast track?
    Chenoweth D
    Drug Discov Today; 2006 Mar; 11(5-6):185-6. PubMed ID: 16580594
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The ODAC Chronicles: Part 3. The FDA's philosophy and process for cancer drug evaluation and approval.
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):1-5. PubMed ID: 15757431
    [No Abstract]   [Full Text] [Related]  

  • 28. The 21st Century Cures Act: can the regulatory framework survive the "cures"?
    Osorio-de-Castro CG; Caetano R; Pepe VL
    Cad Saude Publica; 2015 Sep; 31(9):1807-10. PubMed ID: 26578005
    [No Abstract]   [Full Text] [Related]  

  • 29. Cancer drug approval in the United States, Europe, and Japan.
    Milsted RA
    Adv Cancer Res; 2007; 96():371-91. PubMed ID: 17161686
    [No Abstract]   [Full Text] [Related]  

  • 30. Industry looks to buck bias in emerging 'adaptive' designs.
    Torres C
    Nat Med; 2010 Jun; 16(6):619. PubMed ID: 20526301
    [No Abstract]   [Full Text] [Related]  

  • 31. The complexity of integrating speed and safety in drug development and approval.
    Charo RA
    JAMA Intern Med; 2013 Jul; 173(13):1165-6. PubMed ID: 23568604
    [No Abstract]   [Full Text] [Related]  

  • 32. FDA not NIH can speed new drugs.
    Miller HI
    Nature; 2011 Apr; 472(7342):169. PubMed ID: 21490657
    [No Abstract]   [Full Text] [Related]  

  • 33. FDA approval signals more 'homework' on the horizon in trials.
    Waters H
    Nat Med; 2011 Jul; 17(7):754. PubMed ID: 21738130
    [No Abstract]   [Full Text] [Related]  

  • 34. Chutes and ladders on the critical path:comparative effectiveness, product value, and the use of biomarkers in drug development.
    Woodcock J
    Clin Pharmacol Ther; 2009 Jul; 86(1):12-4. PubMed ID: 19536116
    [No Abstract]   [Full Text] [Related]  

  • 35. Characteristics of orphan drug applications that fail to achieve marketing approval in the USA.
    Heemstra HE; Leufkens HG; Rodgers RP; Xu K; Voordouw BC; Braun MM
    Drug Discov Today; 2011 Jan; 16(1-2):73-80. PubMed ID: 21094692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Expanded access program in the United States and Alimta program for malignant mesothelioma patients].
    Nambu Y
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):284-6. PubMed ID: 17301544
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The needs of the few.
    Nature; 2010 Jul; 466(7303):160. PubMed ID: 20613796
    [No Abstract]   [Full Text] [Related]  

  • 38. Phase 0 trials for anticancer drug development.
    Nat Rev Drug Discov; 2009 Jun; 8(6):442. PubMed ID: 19483703
    [No Abstract]   [Full Text] [Related]  

  • 39. Drug safety sciences and the bottleneck in drug development.
    Watkins PB
    Clin Pharmacol Ther; 2011 Jun; 89(6):788-90. PubMed ID: 21593756
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Accelerated approval seen as triumph and roadblock for cancer drugs.
    Susman E
    J Natl Cancer Inst; 2004 Oct; 96(20):1495-6. PubMed ID: 15494596
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.